The first and only CE-IVD marked PD-L1 test for use in the assessment of patients for whom OPDIVO® (nivolumab) and YERVOY® (ipilimumab) combination treatment is being considered in melanoma.1
PD-L1 IHC 28-8 pharmDx demonstrated clinical results in the phase 3 CheckMate-067 clinical trial.
The CheckMate -067 study was a three armed study of OPDIVO® (nivolumab) monotherapy or OPDIVO in combination with YERVOY® (ipilimumab) versus YERVOY monotherapy
Progression free survival was evaluated across PD-L1 subgroups.
PD-L1 expression as detected by PD-L1 IHC 28-8 pharmDx in melanoma may be used as an aid in the assessment of patients for whom OPDIVO (nivolumab) and YERVOY (ipilimumab) combination treatment is being considered.
PD-L1 IHC 28-8 pharmDx is CE-IVD marked and fully validated with analytical performance having met all pre-determined acceptance criteria for sensitivity, specificity, repeatability, and reproducibility.1
|Selected analytical validation parameters||Results for metastatic melanoma|
*Average Negative Agreement, Average Positive Agreement, and Overall Agreement
|PD-L1 IHC 28-8 pharmDx||SK005|
Required but not included in kit:
EnVision FLEX Wash Buffer, 20x
EnVision FLEX Hematoxylin (Link)
1. PD-L1 IHC 28-8 pharmDx Instruction For Use
2. Clinical Trial: Checkmate 067, CA209067
3. Phillips T, Simmons P, Inzunza H, Cogswell J, Novotny J, Taylor C, Zhang X.
Development of an automated PD-L1 immunohistochemistry (IHC) assay for non.small cell lung cancer. Appl Immunohistochem Mol Morph 2015;8:541-9
Contact your local sales representative
Product details, specification sheet and safety data sheet (SDS).
For in vitro diagnostic use
PD-L1 IHC 28-8 pharmDx is a qualitative immunohistochemical assay using Monoclonal Rabbit Anti-PD-L1, Clone 28-8 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-squamous non-small cell lung cancer (NSCLC) and melanoma tissue using EnVision FLEX visualization system on Autostainer Link 48. PD-L1 protein expression is defined as the percentage of tumor cells exhibiting positive membrane staining at any intensity.
PD-L1 expression as detected by PD-L1 IHC 28-8 pharmDx in non-squamous NSCLC may be associated with enhanced survival from OPDIVO® (nivolumab).
PD-L1 expression as detected by PD-L1 IHC 28-8 pharmDx in melanoma may be used as an aid in the assessment of patients for whom OPDIVO® (nivolumab) and YERVOY® (ipilimumab) combination treatment is being considered.1